Skip to main content
. 2023 Feb 6;49:110–118. doi: 10.1016/j.euros.2022.12.015

Fig. 3.

Fig. 3

Fig. 3

Fig. 3

Kaplan‐Meier analysis of clinical outcomes for patients with metastatic renal cell carcinoma starting 1L systemic treatments. (A) Time on treatment. (B) Time to next treatment. (C) Overall survival. 1L = first-line; Axi = axitinib; CI = confidence interval; Ipi = ipilimumab; Nivo = nivolumab; NR = not reached; Pembro = pembrolizumab; TKI = tyrosine kinase inhibitor.